5 research outputs found
Recommended from our members
Impact of Hydrophilic Side Chains on the Thin Film Transistor Performance of a Benzothieno-Benzothiophene Derivative
Side-chain engineering in molecular semiconductors provides a versatile toolbox for precisely manipulating the material’s processability, crystallographic properties, as well as electronic and optoelectronic characteristics. This study explores the impact of integrating hydrophilic side chains, specifically oligoethylene glycol (OEG) units, into the molecular structure of the small molecule semiconductor, 2,7-bis(2(2-methoxy ethoxy)ethoxy) benzo[b]benzo[4,5] thieno[2,3-d] thiophene (OEG-BTBT). The investigation includes a comprehensive analysis of thin film morphology and crystallographic properties, along with the optimization of deposition parameters for improving the device performance. Despite the anticipated benefits, such as enhanced processability, our investigation into OEG-BTBT-based organic field-effect transistors (OFETs) reveals suboptimal performance marked by a low effective charge carrier mobility, a low on/off ratio, and a high threshold voltage. The study unveils bias stress effects and device degradation attributed to the high ionization energy of OEG-BTBT alongside the hydrophilic nature of the ethylene-glycol moieties, which lead to charge trapping at the dielectric interface. Our findings underscore the need for a meticulous balance between electronic properties and chemical functionalities in molecular semiconductors to achieve stable and efficient performance in organic electronic devices
Recommended from our members
Impact of hydrophilic side chains on the thin film transistor performance of a benzothieno–benzothiophene derivative
Side-chain engineering in molecular semiconductors provides a versatile toolbox for precisely manipulating the material's processability, crystallographic properties, as well as electronic and optoelectronic characteristics.</jats:p
Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn's Disease After Ileocolonic Resection.
BACKGROUND & AIMS: Most patients with Crohn's disease (CD) eventually require an intestinal resection. However, CD frequently recurs after resection. We performed a randomized trial to compare the ability of infliximab vs placebo to prevent CD recurrence. METHODS: We evaluated the efficacy of infliximab in preventing postoperative recurrence of CD in 297 patients at 104 sites worldwide from November 2010 through May 2012. All study patients had undergone ileocolonic resection within 45 days before randomization. Patients were randomly assigned (1:1) to groups given infliximab (5 mg/kg) or placebo every 8 weeks for 200 weeks. The primary end point was clinical recurrence, defined as a composite outcome consisting of a CD Activity Index score >200 and a >/=70-point increase from baseline, and endoscopic recurrence (Rutgeerts score >/=i2, determined by a central reader) or development of a new or re-draining fistula or abscess, before or at week 76. Endoscopic recurrence was a major secondary end point. RESULTS: A smaller proportion of patients in the infliximab group had a clinical recurrence before or at week 76 compared with the placebo group, but this difference was not statistically significant (12.9% vs 20.0%; absolute risk reduction [ARR] with infliximab, 7.1%; 95% confidence interval: -1.3% to 15.5%; P = .097). A significantly smaller proportion of patients in the infliximab group had endoscopic recurrence compared with the placebo group (30.6% vs 60.0%; ARR with infliximab, 29.4%; 95% confidence interval: 18.6% to 40.2%; P /=i2 (22.4% vs 51.3%; ARR with infliximab, 28.9%; 95% confidence interval: 18.4% to 39.4%; P < .001). Patients previously treated with anti-tumor necrosis factor agents or those with more than 1 resection were at greater risk for clinical recurrence. The safety profile of infliximab was similar to that from previous reports. CONCLUSIONS: Infliximab is not superior to placebo in preventing clinical recurrence after CD-related resection. However, infliximab does reduce endoscopic recurrence. ClinicalTrials.gov ID NCT01190839
Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn's Disease after Ileocolonic Resection
BACKGROUND & AIMS: Most patients with Crohn\u2019s disease
(CD) eventually require an intestinal resection. However, CD
frequently recurs after resection. We performed a randomized
trial to compare the ability of infliximab vs placebo to prevent
CD recurrence. METHODS: We evaluated the efficacy of
infliximab in preventing postoperative recurrence of CD in
297 patients at 104 sites worldwide from November 2010
through May 2012. All study patients had undergone ileocolonic
resection within 45 days before randomization. Patients
were randomly assigned (1:1) to groups given infliximab
(5 mg/kg) or placebo every 8 weeks for 200 weeks. The
primary end point was clinical recurrence, defined as a
composite outcome consisting of a CD Activity Index score
>200 and a 70-point increase from baseline, and endoscopic
recurrence (Rutgeerts score i2, determined by a
central reader) or development of a new or re-draining fistula
or abscess, before or at week 76. Endoscopic recurrence was
a major secondary end point. RESULTS: A smaller proportion
of patients in the infliximab group had a clinical recurrence
before or at week 76 compared with the placebo group, but
this difference was not statistically significant (12.9% vs
20.0%; absolute risk reduction [ARR] with infliximab, 7.1%;
95% confidence interval: 1.3% to 15.5%; P \ubc .097). A
significantly smaller proportion of patients in the infliximab
group had endoscopic recurrence compared with the placebo
group (30.6% vs 60.0%; ARR with infliximab, 29.4%; 95%
confidence interval: 18.6% to 40.2%; P < .001). Additionally,
a significantly smaller proportion of patients in the infliximab
group had endoscopic recurrence based only on Rutgeerts
scores i2 (22.4% vs 51.3%; ARR with infliximab,
28.9%; 95% confidence interval: 18.4% to 39.4%; P < .001).
Patients previously treated with anti-tumor necrosis factor
agents or those with more than 1 resection were at greater
risk for clinical recurrence. The safety profile of infliximab
was similar to that from previous reports. CONCLUSIONS:
Infliximab is not superior to placebo in preventing clinical
recurrence after CD-related resection. However, infliximab
does reduce endoscopic recurrence